<\/p>\n
Roliten<\/strong> bevat tolterodinetartraat<\/strong> — a competitive muscarinic acetylcholine receptor antagonist used to treat overactieve blaas (OAB)<\/strong> with urgency, frequency, and urge incontinence. Available as 1 mg immediate-release tablets. Standard dose: 2 mg twice daily<\/strong> (or 1 mg twice daily in renal\/hepatic impairment or with strong CYP3A4 inhibitors). For convenient once-daily dosing with smoother side-effect profile, see the extended-release formulation (Terol LA)<\/a>. Tolterodine is generally better tolerated than oxybutynin<\/strong> — less dry mouth, less constipation, and lower CNS penetration. Use with caution in adults aged 65+<\/strong> — the 2023 American Geriatrics Society Beers Criteria classifies all anticholinergic OAB drugs as “potentially inappropriate” in older adults due to cumulative anticholinergic burden. Mirabegron (Mirago)<\/strong> is the preferred first-line OAB drug in this population.<\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n <\/p>\n Elke batch wordt ingekocht bij een WHO-GMP gecertificeerde fabrikant<\/strong>. Bestellingen worden verzonden in eenvoudige, ongemarkeerde verpakkingen door onze logistieke partners en vallen onder onze Reshipment Assurance Policy<\/a>: als een pakket niet binnen 20 werkdagen arriveert, sturen wij kosteloos een nieuwe zending, zonder vragen te stellen.<\/p>\n Roliten is a brand of tolterodine tartrate 1 mg immediate-release tablets<\/strong>. Tolterodine is one of the most-prescribed antimuscarinic OAB drugs worldwide. Internationally branded as Detrol \/ Detrol LA (US), Detrusitol \/ Detrusitol XL (UK \/ EU)<\/strong>. Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets\/capsules.<\/p>\n Tolterodine is a competitive antagonist at M2 and M3 muscarinic acetylcholine receptors<\/strong>. Bladder M3 blockade reduces parasympathetic-driven detrusor contractions during the filling phase — decreasing urgency and incontinence episodes and increasing functional bladder capacity.<\/p>\n In vergelijking met oxybutynin<\/a>, tolterodine has somewhat better selectivity for bladder vs salivary-gland muscarinic receptors, lower CNS penetration, and a more favourable side-effect profile — particularly less severe dry mouth. Both are still anticholinergics with the standard class warnings about elderly use.<\/p>\n Tolterodine is metabolised by CYP2D6 to an active metabolite (5-hydroxymethyl tolterodine) which contributes substantially to clinical effect. About 5-10% of the population are CYP2D6 “poor metabolisers” who form less of the metabolite and need dose adjustment.<\/p>\n Tolterodine has somewhat lower CNS penetration than oxybutynin and is generally considered the better-tolerated of the two anticholinergic OAB drugs in older adults — but it is still classified as “potentially inappropriate” in the Beers Criteria and should be used cautiously and at the lowest effective dose. Mirabegron remains the preferred first-line OAB drug in adults aged 65+<\/strong> when affordable and not contraindicated by hypertension.<\/p>\n Do not take tolterodine if you have:<\/strong><\/p>\n Wees voorzichtig bij:<\/strong> elderly age (see above), benign prostatic hyperplasia (urinary retention risk), reflux oesophagitis, autonomic neuropathy, congenital or acquired QT prolongation, coronary artery disease.<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
\n
What is Roliten?<\/h2>\n
How tolterodine works<\/h2>\n
When tolterodine is used<\/h2>\n
\n
Dosering & hoe in te nemen<\/h2>\n
\n
Bijwerkingen & veiligheid<\/h2>\n
\n
Anticholinergic burden & the elderly<\/h2>\n
Contra-indicaties & waarschuwingen<\/h2>\n
\n
Geneesmiddelinteracties<\/h2>\n
\n
How tolterodine compares<\/h2>\n